DK2643019T3 - ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE - Google Patents
ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE Download PDFInfo
- Publication number
- DK2643019T3 DK2643019T3 DK11843652.6T DK11843652T DK2643019T3 DK 2643019 T3 DK2643019 T3 DK 2643019T3 DK 11843652 T DK11843652 T DK 11843652T DK 2643019 T3 DK2643019 T3 DK 2643019T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41692710P | 2010-11-24 | 2010-11-24 | |
| PCT/US2011/061785 WO2012071381A1 (en) | 2010-11-24 | 2011-11-22 | Antibodies to notum pectinacetylesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2643019T3 true DK2643019T3 (en) | 2019-04-15 |
Family
ID=46146184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11843652.6T DK2643019T3 (en) | 2010-11-24 | 2011-11-22 | ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130302346A1 (OSRAM) |
| EP (1) | EP2643019B1 (OSRAM) |
| JP (1) | JP6033229B2 (OSRAM) |
| KR (2) | KR20180069083A (OSRAM) |
| CN (1) | CN103298490B (OSRAM) |
| AU (1) | AU2011332007C1 (OSRAM) |
| BR (1) | BR112013012858B1 (OSRAM) |
| CA (1) | CA2817415C (OSRAM) |
| CO (1) | CO6721048A2 (OSRAM) |
| DK (1) | DK2643019T3 (OSRAM) |
| ES (1) | ES2718849T3 (OSRAM) |
| HU (1) | HUE043576T2 (OSRAM) |
| IL (1) | IL225876A0 (OSRAM) |
| MX (2) | MX357166B (OSRAM) |
| NZ (1) | NZ609501A (OSRAM) |
| PL (1) | PL2643019T3 (OSRAM) |
| PT (1) | PT2643019T (OSRAM) |
| RU (1) | RU2013123793A (OSRAM) |
| SG (1) | SG189982A1 (OSRAM) |
| WO (1) | WO2012071381A1 (OSRAM) |
| ZA (1) | ZA201302983B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201506782XA (en) * | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
| EP2643019B1 (en) | 2010-11-24 | 2019-01-02 | Lexicon Pharmaceuticals, Inc. | Antibodies to notum pectinacetylesterase |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| US8802365B2 (en) * | 2011-03-22 | 2014-08-12 | Whitehead Institute For Biomedical Research | Methods for identifying candidate modulators of NOTUM activity |
| DK2890711T3 (en) * | 2012-08-31 | 2017-02-27 | Argen-X Nv | Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules |
| PT3653221T (pt) | 2015-02-19 | 2022-11-08 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| CN110317271B (zh) * | 2019-07-02 | 2021-04-30 | 武汉云克隆科技股份有限公司 | 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体 |
| EP4263613A4 (en) * | 2020-12-16 | 2024-11-20 | Memorial Sloan-Kettering Cancer Center | CD40-BINDING MOLECULES AND USES THEREOF |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW313568B (OSRAM) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6080576A (en) | 1998-03-27 | 2000-06-27 | Lexicon Genetics Incorporated | Vectors for gene trapping and gene activation |
| GB0201808D0 (en) * | 2002-01-25 | 2002-03-13 | European Molecular Biology Lab Embl | Protein |
| US20040063924A1 (en) * | 2002-01-28 | 2004-04-01 | Y Tom Tang | Secreted proteins |
| EP1652923B1 (en) * | 2003-08-08 | 2011-10-12 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
| SG10201506782XA (en) * | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
| EP2643019B1 (en) | 2010-11-24 | 2019-01-02 | Lexicon Pharmaceuticals, Inc. | Antibodies to notum pectinacetylesterase |
-
2011
- 2011-11-22 EP EP11843652.6A patent/EP2643019B1/en not_active Not-in-force
- 2011-11-22 BR BR112013012858-5A patent/BR112013012858B1/pt not_active IP Right Cessation
- 2011-11-22 DK DK11843652.6T patent/DK2643019T3/en active
- 2011-11-22 PL PL11843652T patent/PL2643019T3/pl unknown
- 2011-11-22 SG SG2013031083A patent/SG189982A1/en unknown
- 2011-11-22 KR KR1020187016214A patent/KR20180069083A/ko not_active Ceased
- 2011-11-22 US US13/885,815 patent/US20130302346A1/en not_active Abandoned
- 2011-11-22 WO PCT/US2011/061785 patent/WO2012071381A1/en not_active Ceased
- 2011-11-22 NZ NZ609501A patent/NZ609501A/en not_active IP Right Cessation
- 2011-11-22 CA CA2817415A patent/CA2817415C/en active Active
- 2011-11-22 AU AU2011332007A patent/AU2011332007C1/en not_active Ceased
- 2011-11-22 MX MX2013005906A patent/MX357166B/es active IP Right Grant
- 2011-11-22 RU RU2013123793/10A patent/RU2013123793A/ru not_active Application Discontinuation
- 2011-11-22 CN CN201180056452.6A patent/CN103298490B/zh not_active Expired - Fee Related
- 2011-11-22 MX MX2018001218A patent/MX385858B/es unknown
- 2011-11-22 KR KR1020137013390A patent/KR20140026334A/ko not_active Ceased
- 2011-11-22 HU HUE11843652A patent/HUE043576T2/hu unknown
- 2011-11-22 ES ES11843652T patent/ES2718849T3/es active Active
- 2011-11-22 JP JP2013541012A patent/JP6033229B2/ja not_active Expired - Fee Related
- 2011-11-22 PT PT11843652T patent/PT2643019T/pt unknown
-
2013
- 2013-04-22 IL IL225876A patent/IL225876A0/en active IP Right Grant
- 2013-04-24 ZA ZA2013/02983A patent/ZA201302983B/en unknown
- 2013-06-24 CO CO13149527A patent/CO6721048A2/es not_active Application Discontinuation
-
2015
- 2015-11-25 US US14/952,264 patent/US20160152731A1/en not_active Abandoned
-
2019
- 2019-02-15 US US16/277,466 patent/US11059907B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2643019T3 (en) | ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE | |
| AU2020294193B2 (en) | Anti-pro/latent-Myostatin antibodies and uses thereof | |
| KR102596852B1 (ko) | 항-프로/잠재성-미오스타틴 항체 및 그의 용도 | |
| JP6272793B2 (ja) | プロガストリンに対するモノクローナル抗体及びその使用 | |
| CA2508214A1 (en) | Antibodies directed to phospholipase a2 and uses thereof | |
| WO2021063352A1 (zh) | 一种抗pd-l1抗原结合蛋白及其应用 | |
| KR20230079419A (ko) | 항-스클레로스틴 구축물 및 이의 용도 | |
| HK1189166A (en) | Antibodies to notum pectinacetylesterase | |
| HK1189166B (en) | Antibodies to notum pectinacetylesterase | |
| CN114106163A (zh) | SARS-CoV-2病毒中和抗体及其用途 | |
| HK40049635A (en) | Anti-pd-l1 antigen binding protein, and application thereof | |
| HK40049635B (en) | Anti-pd-l1 antigen binding protein, and application thereof |